Brief: Akeso Says NMPA Accepted Supplemental New Drug Application For Cadonilimab
24/04/2024 01:21
April 24 (Reuters) - Akeso Inc 9926.HK :
* NMPA ACCEPTED SUPPLEMENTAL NEW DRUG APPLICATION FOR
CADONILIMAB
* ACCEPTED APPLICATION FOR CADONILIMAB AS FIRST-LINE
TREATMENT FOR
CERVICAL CANCER
Further company coverage: 9926.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals